


-64-

WE CLAIM:

1. A compound of the formula:



- 5 wherein:

R1a is hydrogen, methyl, ethenyl, cyano, fluoro, chloro, fluoromethyl, or difluoromethyl;

R1b is hydrogen, fluoro, or chloro;


R1c is hydrogen, hydroxy, fluoro, benzyloxy, or hydroxyethylamino;

- 10 R2 is hydrogen or methyl;


R2a is hydrogen or methyl; and

R3a is tetrahydropyranyl.

2. The compound according to claim 1 which is:




- 15 3. The compound according to either claim 1 or claim 2 which is:



4. The compound according to either claim 1 or claim 2 which is

-65-



5. The compound according to any one of claims 1-3 which is crystalline 4-fluoro-N-[(1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl]benzamide.
- 5 6. The compound according to claim 5 which is crystalline 4-fluoro-N-[(1R)-1-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-2,3-dihydro-1H-indol-5-yl]ethyl]benzamide characterized by an X-ray powder diffraction pattern (Cu radiation,  $\lambda$ -1.54060 Å) comprising at least one peak at 17.38° in combination with one or more peaks selected from the group consisting of 12.51°, 15.65°, 16.37°, 17.56°, 21.48° and 25.23° ( $2\theta \pm 0.2^\circ$ ).
- 10 7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 with one or more pharmaceutically acceptable excipients, carriers or diluents.
8. A method of treating a patient with a cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma comprising administering to the patient an effective amount of a compound according to any one of claims 1-6.
- 15 9. A compound according to any one of claims 1-6 for use in therapy.
10. A compound according to any one of claims 1-6 for use in cancer.
11. A compound according to claim 10 wherein the cancer is selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
- 25